Endocrine Pathology — MCQs
On this page
All of the following are features of medullary carcinoma of thyroid, except:
What is the commonest cause of Cushing's syndrome?
A 58-year-old patient presents with increased "fullness" in her neck. Examination reveals non-tender, diffuse enlargement of her thyroid gland. Clinically, she is euthyroid. Microscopic examination of her thyroid gland reveals numerous, mainly enlarged follicles filled with abundant colloid material. There are areas of fibrosis, hemorrhage, and cystic degeneration. No papillary structures are identified, and neither colloid scalloping nor Hurthle cells are present. What is the most likely diagnosis?
Gs-alpha mutation may lead to which of the following conditions?
Autoimmune thyroiditis is commonly associated with which of the following conditions?
In diseases, cell death of growth hormone cells occurs by which mechanism?
A biopsy from a mass shows parafollicular cells. What is the tumor marker?
A patient presents with secondary malignancy in the adrenal glands. What is the most common primary site for such metastases?
A patient presents with a pituitary tumor, pheochromocytoma, and a thyroid nodule. Which type of thyroid cancer is most likely to occur?
A 45-year-old male was evaluated for secondary hypertension and diagnosed with pheochromocytoma. MRI abdomen revealed a 3 cm mass in the left adrenal gland. He underwent a left adrenalectomy, after which his hypertension is well controlled. How will you decide whether his pheochromocytoma was malignant?
Endocrine Pathology Indian Medical PG Practice Questions and MCQs
Question 101: All of the following are features of medullary carcinoma of thyroid, except:
- A. Arises from parafollicular cells or C-cells
- B. Known association with MEN-2A or MEN-2B syndromes
- C. RAS gene mutations play an important role in its tumourigenesis (Correct Answer)
- D. Tumour cells secrete calcitonin
Explanation: **Explanation:** Medullary Thyroid Carcinoma (MTC) is a neuroendocrine neoplasm that differs significantly from other thyroid cancers in its origin and molecular profile [3]. **Why Option C is the correct answer (The Exception):** The hallmark molecular driver of Medullary Thyroid Carcinoma is the **RET proto-oncogene mutation**, not RAS. RET mutations are found in nearly 100% of hereditary cases and approximately 50% of sporadic cases. In contrast, **RAS mutations** are typically associated with **Follicular Thyroid Carcinoma** and the follicular variant of Papillary Thyroid Carcinoma [3]. **Analysis of Incorrect Options:** * **Option A:** MTC arises from the **parafollicular cells (C-cells)**, which are derived from the neural crest (ultimobranchial body), unlike other thyroid cancers which arise from follicular epithelium [2]. * **Option B:** Approximately 20-25% of MTC cases are hereditary, occurring as part of **MEN-2A or MEN-2B** syndromes (autosomal dominant) [1, 5]. * **Option D:** Since C-cells normally produce **calcitonin**, MTC cells also secrete it. Serum calcitonin serves as a highly specific tumor marker for diagnosis and monitoring recurrence [1, 4]. **High-Yield Clinical Pearls for NEET-PG:** * **Amyloid Stroma:** Histologically, MTC is characterized by acellular amyloid deposits (derived from altered calcitonin) that stain with **Congo Red** (apple-green birefringence) [4]. * **IHC Markers:** Positive for Calcitonin, Chromogranin A, and Synaptophysin. * **Screening:** In families with known RET mutations, prophylactic thyroidectomy is often indicated. * **CEA:** Carcinoembryonic antigen (CEA) is also often elevated and used as a secondary tumor marker [1]. **References:** [1] Kumar V, Abbas AK, et al.. Robbins and Cotran Pathologic Basis of Disease. 9th ed. The Endocrine System, pp. 1102-1103. [2] Cross SS. Underwood's Pathology: A Clinical Approach. 6th ed. Common Clinical Problems From Liver And Biliary System Disease, pp. 428-429. [3] Kumar V, Abbas AK, et al.. Robbins and Cotran Pathologic Basis of Disease. 9th ed. The Endocrine System, pp. 1097-1098. [4] Cross SS. Underwood's Pathology: A Clinical Approach. 6th ed. Common Clinical Problems From Liver And Biliary System Disease, pp. 430-431. [5] Kumar V, Abbas AK, et al.. Robbins and Cotran Pathologic Basis of Disease. 9th ed. The Endocrine System, pp. 1139-1140.
Question 102: What is the commonest cause of Cushing's syndrome?
- A. Adrenal adenoma
- B. Adrenocortical carcinoma
- C. Adrenal atrophy
- D. Adrenal hyperplasia (Correct Answer)
Explanation: **Explanation:** The correct answer is **Adrenal hyperplasia**. To answer this question correctly, it is vital to distinguish between the **etiology** (the source of the problem) and the **morphological change** in the adrenal glands [2]. 1. **Why Adrenal Hyperplasia is correct:** Cushing’s syndrome refers to the clinical state of chronic hypercortisolism. The most common cause overall (approx. 70-80%) is **Exogenous (Iatrogenic) steroid administration**. However, among endogenous causes, **Cushing’s Disease** (an ACTH-secreting pituitary adenoma) is the most frequent (approx. 70%) [3]. In both Cushing’s Disease and Ectopic ACTH syndrome, the chronically elevated ACTH levels overstimulate the adrenal cortex, leading to **bilateral adrenal hyperplasia** [2]. Therefore, hyperplasia is the most common pathological finding in the adrenals in endogenous Cushing's syndrome. 2. **Why the other options are incorrect:** * **Adrenal Adenoma & Carcinoma:** These are primary adrenal causes (ACTH-independent). While they cause Cushing’s syndrome, they are significantly less common than ACTH-dependent causes [1]. * **Adrenal Atrophy:** This occurs in the contralateral gland when a unilateral functional tumor is present, or bilaterally in **Exogenous steroid use** (due to feedback inhibition of ACTH) [2]. While exogenous use is the "commonest cause" of the syndrome, "Atrophy" is a regressive change, whereas the question typically looks for the proliferative cause of endogenous hypercortisolism. **High-Yield Pearls for NEET-PG:** * **Most common cause of Cushing Syndrome:** Exogenous steroids (leads to bilateral adrenal atrophy) [2]. * **Most common Endogenous cause:** Cushing’s Disease (Pituitary adenoma) [3]. * **Most common Adrenal morphology in Endogenous Cushing's:** Bilateral Diffuse Hyperplasia. * **Ectopic ACTH:** Most commonly associated with Small Cell Carcinoma of the Lung; presents with very high ACTH and bilateral adrenal hyperplasia. **References:** [1] Kumar V, Abbas AK, et al.. Robbins and Cotran Pathologic Basis of Disease. 9th ed. The Endocrine System, pp. 1127-1129. [2] Kumar V, Abbas AK, et al.. Robbins and Cotran Pathologic Basis of Disease. 9th ed. The Endocrine System, p. 1127. [3] Kumar V, Abbas AK, et al.. Robbins and Cotran Pathologic Basis of Disease. 9th ed. The Endocrine System, pp. 1082-1083.
Question 103: A 58-year-old patient presents with increased "fullness" in her neck. Examination reveals non-tender, diffuse enlargement of her thyroid gland. Clinically, she is euthyroid. Microscopic examination of her thyroid gland reveals numerous, mainly enlarged follicles filled with abundant colloid material. There are areas of fibrosis, hemorrhage, and cystic degeneration. No papillary structures are identified, and neither colloid scalloping nor Hurthle cells are present. What is the most likely diagnosis?
- A. Colloid carcinoma
- B. Diffuse toxic goiter
- C. Graves disease
- D. Multinodular goiter (Correct Answer)
Explanation: ### Explanation **Correct Answer: D. Multinodular goiter (MNG)** **Why it is correct:** The clinical and pathological features described are classic for **Multinodular Goiter**. MNG typically presents in older adults as a non-tender, diffuse, or irregular enlargement of the thyroid gland [1]. Patients are usually **euthyroid** (unlike Graves disease). Histologically, the hallmark is **heterogeneity**: follicles of varying sizes, many of which are dilated and filled with **abundant, flat-looking colloid** [2]. Over time, these glands undergo secondary changes due to repeated cycles of hyperplasia and involution, leading to **fibrosis, hemorrhage, and cystic degeneration**, as seen in this case [1]. **Why the other options are incorrect:** * **A. Colloid carcinoma:** This is not a standard pathological entity. While "Colloid carcinoma" exists in the breast or pancreas (mucinous carcinoma), it is not a recognized primary thyroid malignancy. * **B & C. Diffuse toxic goiter / Graves disease:** These are synonymous. Clinically, patients present with **hyperthyroidism** (tachycardia, weight loss, exophthalmos). Histologically, Graves is characterized by **colloid scalloping** (due to active resorption) and tall, columnar epithelial cells, both of which are specifically absent in this description [3]. **NEET-PG High-Yield Pearls:** * **Plummer Syndrome:** A multinodular goiter that develops autonomous nodules, leading to hyperthyroidism (Toxic MNG). Unlike Graves, it lacks infiltrative ophthalmopathy. * **Dominant Nodule:** In MNG, one nodule may grow significantly larger than others, mimicking a neoplasm. Fine Needle Aspiration (FNA) is often required to rule out malignancy. * **Pemberton Sign:** Facial flushing and inspiratory stridor when arms are raised, indicating a large MNG causing thoracic inlet obstruction. * **Histology Tip:** If you see "Hurthle cells" and "lymphocytic infiltrates," think Hashimoto’s Thyroiditis. If you see "Orphan Annie eyes," think Papillary Carcinoma. **References:** [1] Kumar V, Abbas AK, et al.. Robbins and Cotran Pathologic Basis of Disease. 9th ed. The Endocrine System, pp. 1094-1095. [2] Kumar V, Abbas AK, et al.. Robbins and Cotran Pathologic Basis of Disease. 9th ed. The Endocrine System, pp. 1093-1094. [3] Kumar V, Abbas AK, et al.. Robbins and Cotran Pathologic Basis of Disease. 9th ed. The Endocrine System, p. 1093.
Question 104: Gs-alpha mutation may lead to which of the following conditions?
- A. McCune-Albright syndrome
- B. Pseudohypoparathyroidism
- C. Pseudopseudohypoparathyroidism
- D. All of the above (Correct Answer)
Explanation: The **Gs-alpha (GNAS1) gene** encodes the alpha subunit of the stimulatory G-protein, which is essential for transmembrane signaling [2]. Mutations in this gene lead to diverse clinical phenotypes depending on whether the mutation is **activating** (gain-of-function) or **inactivating** (loss-of-function), and whether it is somatic or germline. ### Explanation of Options: * **McCune-Albright Syndrome (MAS):** This is caused by a **somatic activating mutation** in GNAS1 during early embryogenesis [1], [3]. This leads to constitutive activation of adenylate cyclase, resulting in the classic triad of polyostotic fibrous dysplasia, café-au-lait spots, and autonomous endocrine hyperfunction (e.g., precocious puberty) [1], [3]. * **Pseudohypoparathyroidism (PHP) Type 1a:** This is caused by a **germline inactivating mutation** in the maternal allele of GNAS1. It results in end-organ resistance to Parathyroid Hormone (PTH), leading to hypocalcemia and hyperphosphatemia, alongside the **Albright Hereditary Osteodystrophy (AHO)** phenotype (short stature, round face, short 4th/5th metacarpals). * **Pseudopseudohypoparathyroidism (PPHP):** This occurs when the **germline inactivating mutation** is inherited from the father. Due to tissue-specific imprinting, these patients exhibit the AHO phenotype but have **normal** calcium and PTH levels (no hormone resistance). ### High-Yield Clinical Pearls for NEET-PG: * **GNAS1 Imprinting:** The gene is paternally silenced in the proximal renal tubules; hence, only maternal mutations cause PTH resistance (PHP 1a). * **Mosaicism:** McCune-Albright syndrome must be mosaic to be compatible with life; a germline activating mutation would be lethal. * **Test-Taking Tip:** If a question mentions "short 4th metacarpal" or "Archibald’s sign," think of GNAS1 mutations (AHO phenotype). **References:** [1] Kumar V, Abbas AK, et al.. Robbins and Cotran Pathologic Basis of Disease. 9th ed. The Endocrine System, pp. 1126-1127. [2] Kumar V, Abbas AK, et al.. Robbins and Cotran Pathologic Basis of Disease. 9th ed. The Endocrine System, pp. 1079-1081. [3] Kumar V, Abbas AK, et al.. Robbins and Cotran Pathologic Basis of Disease. 9th ed. Bones, Joints, and Soft Tissue Tumors, p. 1208.
Question 105: Autoimmune thyroiditis is commonly associated with which of the following conditions?
- A. Down syndrome (Correct Answer)
- B. Marfan syndrome
- C. Lowe syndrome
- D. Edwards syndrome
Explanation: **Explanation:** **1. Why Down Syndrome is Correct:** Down syndrome (Trisomy 21) is strongly associated with an increased risk of autoimmune disorders, particularly **Autoimmune Thyroid Disease (AITD)**. Both Hashimoto thyroiditis (hypothyroidism) and Graves’ disease (hyperthyroidism) occur at a significantly higher frequency in these patients compared to the general population. The underlying mechanism involves immune dysregulation caused by the extra copy of chromosome 21, which carries genes involved in immune response regulation (e.g., *AIRE* gene and *interferon receptors*), leading to a breakdown in self-tolerance. **2. Why Other Options are Incorrect:** * **Marfan Syndrome:** This is a connective tissue disorder caused by mutations in the *FBN1* gene (Fibrillin-1). It presents with skeletal, ocular, and cardiovascular issues (e.g., aortic dissection) but has no established link to autoimmune thyroiditis. * **Lowe Syndrome (Oculocerebrorenal syndrome):** An X-linked recessive disorder characterized by congenital cataracts, mental retardation, and renal Fanconi syndrome. It does not involve autoimmune endocrine pathology. * **Edwards Syndrome (Trisomy 18):** Characterized by severe multi-system defects (rocker-bottom feet, clenched fists, micrognathia). Most patients do not survive infancy, and it is not typically associated with autoimmune thyroiditis. **3. Clinical Pearls for NEET-PG:** * **Screening:** Due to the high prevalence, children with Down syndrome should have annual thyroid function tests (TFTs). * **Other Associations:** Down syndrome is also associated with **Celiac disease**, Type 1 Diabetes [1], and an increased risk of **Alzheimer’s disease** (due to the APP gene on chromosome 21) and **Acute Leukemia** (AMKL and ALL). * **Most Common Cause:** Hashimoto thyroiditis is the most common cause of hypothyroidism in iodine-sufficient regions and is characterized by Hurthle cells and lymphocytic infiltration on histology [1]. **References:** [1] Kumar V, Abbas AK, et al.. Robbins and Cotran Pathologic Basis of Disease. 9th ed. The Endocrine System, pp. 1089-1090.
Question 106: In diseases, cell death of growth hormone cells occurs by which mechanism?
- A. Aging
- B. Apoptosis (Correct Answer)
- C. Necrosis
- D. All of the above
Explanation: The correct answer is **Apoptosis**. **Why Apoptosis is correct:** In the context of endocrine pathology, the regulation of hormone-secreting cells is a highly controlled process. When the physiological demand for a hormone decreases or when specific pathological triggers occur (such as the withdrawal of trophic hormones or specific feedback inhibition), the corresponding cells undergo **programmed cell death**, or **apoptosis** [1]. Specifically, in the anterior pituitary, the loss of growth hormone-secreting cells (somatotrophs) in various disease states or physiological shifts is mediated by the activation of caspases, leading to cell shrinkage and fragmentation without an inflammatory response [2]. **Why other options are incorrect:** * **Aging:** While aging leads to a functional decline in the somatotropic axis (somatopause), it is a chronological process rather than the primary *mechanism* of acute or disease-induced cell death [3]. * **Necrosis:** Necrosis is accidental, uncontrolled cell death resulting from severe external injury (e.g., ischemia in Sheehan’s syndrome) [3]. While it occurs in pituitary infarction, it is not the standard mechanism for the selective loss of specific cell types like growth hormone cells in general disease states. * **All of the above:** Since apoptosis is the specific programmed mechanism for selective cell deletion in endocrine regulation, this option is incorrect. **References:** [1] Kumar V, Abbas AK, et al.. Robbins and Cotran Pathologic Basis of Disease. 9th ed. Cellular Responses to Stress and Toxic Insults: Adaptation, Injury, and Death, pp. 63-64. [2] Kumar V, Abbas AK, et al.. Robbins and Cotran Pathologic Basis of Disease. 9th ed. Cellular Responses to Stress and Toxic Insults: Adaptation, Injury, and Death, pp. 64-65. [3] Kumar V, Abbas AK, et al.. Robbins and Cotran Pathologic Basis of Disease. 9th ed. Cellular Responses to Stress and Toxic Insults: Adaptation, Injury, and Death, p. 45.
Question 107: A biopsy from a mass shows parafollicular cells. What is the tumor marker?
- A. Calcitonin (Correct Answer)
- B. T4
- C. Thyroxine
- D. Thyroglobulin
Explanation: **Explanation:** The correct answer is **Calcitonin**. **1. Why Calcitonin is Correct:** The thyroid gland contains two distinct endocrine cell populations: follicular cells and **parafollicular cells (C-cells)**. Parafollicular cells are derived from the neural crest (ultimobranchial body) and are responsible for the synthesis and secretion of **Calcitonin** [1], a hormone that lowers blood calcium levels. When these cells undergo neoplastic transformation, they result in **Medullary Thyroid Carcinoma (MTC)** [4]. Therefore, Calcitonin serves as the definitive tumor marker for diagnosis and monitoring recurrence in MTC [2]. **2. Why Other Options are Incorrect:** * **T4 and Thyroxine (Options B & C):** These are the same hormone. They are produced by the **follicular cells** of the thyroid gland, not the parafollicular cells [1]. While they reflect thyroid function, they are not used as specific tumor markers for thyroid malignancies. * **Thyroglobulin (Option D):** This is a glycoprotein produced exclusively by **follicular cells**. It is used as a tumor marker for differentiated thyroid cancers, specifically **Papillary and Follicular Thyroid Carcinoma**, but it is not produced by parafollicular cells. **High-Yield Clinical Pearls for NEET-PG:** * **Medullary Thyroid Carcinoma (MTC):** Associated with **MEN 2A and 2B** syndromes (RET proto-oncogene mutations) [2]. * **Histology:** Characterized by polygonal cells in nests with **amyloid stroma** (derived from pro-calcitonin), which stains with **Congo Red** (apple-green birefringence) [3]. * **CEA (Carcinoembryonic Antigen):** Also used as a secondary tumor marker for MTC [2]. * **Origin:** Parafollicular cells are located in the upper two-thirds of the thyroid lobes. **References:** [1] Cross SS. Underwood's Pathology: A Clinical Approach. 6th ed. Common Clinical Problems From Liver And Biliary System Disease, pp. 424-426. [2] Kumar V, Abbas AK, et al.. Robbins and Cotran Pathologic Basis of Disease. 9th ed. The Endocrine System, pp. 1102-1103. [3] Cross SS. Underwood's Pathology: A Clinical Approach. 6th ed. Common Clinical Problems From Liver And Biliary System Disease, pp. 430-431. [4] Cross SS. Underwood's Pathology: A Clinical Approach. 6th ed. Common Clinical Problems From Liver And Biliary System Disease, pp. 428-429.
Question 108: A patient presents with secondary malignancy in the adrenal glands. What is the most common primary site for such metastases?
- A. Lung (Correct Answer)
- B. Kidney
- C. Breast
- D. Stomach
Explanation: **Explanation:** The adrenal glands are highly vascular organs, making them a frequent site for hematogenous metastasis. In fact, metastatic disease is the most common cause of a non-functioning adrenal mass. **1. Why Lung is Correct:** Carcinoma of the **Lung** is the most common primary source of adrenal metastasis [1]. This is attributed to the rich sinusoidal blood supply of the adrenal cortex, which traps circulating tumor cells. In clinical practice, when a patient with a known lung malignancy presents with an adrenal mass, it is statistically more likely to be a secondary deposit than a primary adrenal cortical carcinoma. **2. Analysis of Incorrect Options:** * **Kidney (B):** While Renal Cell Carcinoma (RCC) can spread to the adrenals due to anatomical proximity and venous drainage, it is less frequent than lung primaries. * **Breast (C):** Breast cancer is the second most common primary site for adrenal metastasis, particularly in females, but it trails behind lung cancer in overall incidence. * **Stomach (D):** Gastric carcinomas typically metastasize to the liver, peritoneum, or Virchow’s node; adrenal involvement is rare compared to thoracic malignancies. **3. High-Yield Pearls for NEET-PG:** * **Order of Frequency:** Lung > Breast > Stomach > Pancreas > Colon. * **Clinical Presentation:** Most adrenal metastases are asymptomatic and discovered incidentally ("incidentalomas"). They rarely cause adrenal insufficiency (Addison’s disease) unless >90% of the gland is destroyed bilaterally. * **Imaging:** On CT/MRI, metastases typically show lower lipid content and slower contrast washout compared to benign adrenal adenomas. * **Primary vs. Secondary:** Metastatic disease is significantly more common than primary Adrenocortical Carcinoma (ACC). **References:** [1] Kumar V, Abbas AK, et al.. Robbins and Cotran Pathologic Basis of Disease. 9th ed. The Lung, pp. 724-725.
Question 109: A patient presents with a pituitary tumor, pheochromocytoma, and a thyroid nodule. Which type of thyroid cancer is most likely to occur?
- A. Follicular carcinoma
- B. Medullary carcinoma (Correct Answer)
- C. Papillary carcinoma
- D. Anaplastic carcinoma
Explanation: ### Explanation The patient presents with a classic triad of tumors suggesting **Multiple Endocrine Neoplasia (MEN) Type 1 and 2 overlap features**, specifically pointing toward a syndromic association. The presence of a **pheochromocytoma** and a **thyroid nodule** is the hallmark of **MEN 2 (Sipple Syndrome)** [1]. **Why Medullary Carcinoma is Correct:** Medullary Thyroid Carcinoma (MTC) is a neuroendocrine tumor derived from **parafollicular C-cells** (which secrete calcitonin) [2]. It is a mandatory component of both **MEN 2A and MEN 2B** [1]. In the context of a pheochromocytoma, MTC is the most likely diagnosis [3]. While pituitary tumors are typically associated with MEN 1 (Wermer Syndrome), clinical scenarios in exams often combine these features to test your knowledge of the specific cancers associated with germline mutations (like the **RET proto-oncogene** in MTC) [1]. **Why Incorrect Options are Wrong:** * **Papillary Carcinoma (C):** The most common thyroid cancer overall, associated with *BRAF* mutations and radiation exposure, but not typically part of the MEN syndromes. * **Follicular Carcinoma (A):** Associated with iodine deficiency and *RAS* mutations/PAX8-PPAR\u03b3 rearrangements; it does not occur as part of MEN syndromes. * **Anaplastic Carcinoma (D):** A highly aggressive, undifferentiated tumor seen in elderly patients; it is not associated with pheochromocytoma or pituitary adenomas. **High-Yield NEET-PG Pearls:** * **MEN 2A:** Medullary Thyroid Ca + Pheochromocytoma + Parathyroid Hyperplasia [1]. * **MEN 2B:** Medullary Thyroid Ca + Pheochromocytoma + Mucosal Neuromas/Marfanoid habitus [1]. * **Genetics:** All MEN 2 variants are associated with **RET proto-oncogene** mutations [1]. * **Diagnosis:** MTC is identified by **amyloid stroma** (Congo Red positive) and elevated **Serum Calcitonin** levels [2]. **References:** [1] Kumar V, Abbas AK, et al.. Robbins and Cotran Pathologic Basis of Disease. 9th ed. The Endocrine System, p. 1137. [2] Cross SS. Underwood's Pathology: A Clinical Approach. 6th ed. Common Clinical Problems From Liver And Biliary System Disease, pp. 430-431. [3] Kumar V, Abbas AK, et al.. Robbins and Cotran Pathologic Basis of Disease. 9th ed. The Endocrine System, pp. 1102-1103.
Question 110: A 45-year-old male was evaluated for secondary hypertension and diagnosed with pheochromocytoma. MRI abdomen revealed a 3 cm mass in the left adrenal gland. He underwent a left adrenalectomy, after which his hypertension is well controlled. How will you decide whether his pheochromocytoma was malignant?
- A. Approximately 50% of pheochromocytomas are malignant.
- B. Cellular atypia and invasion of blood vessels on pathology define malignancy for pheochromocytoma.
- C. 123I-metaiodobenzylguanidine scans are not useful in locating distant metastases.
- D. The presence or absence of distant metastases is the primary determinant of malignancy. (Correct Answer)
Explanation: The diagnosis of malignancy in pheochromocytoma is unique in pathology. Unlike most other tumors, histological features such as cellular pleomorphism, mitotic activity, or even local vascular invasion are **not** definitive indicators of malignancy [1]. **1. Why Option D is Correct:** The only absolute criterion for diagnosing a malignant pheochromocytoma is the **presence of distant metastases** to sites where chromaffin tissue is not normally found (e.g., bone, liver, lungs, or lymph nodes). This is because benign pheochromocytomas can often exhibit "worrisome" histological features (atypia, capsular invasion) without ever metastasizing, while histologically "bland" tumors may spread aggressively [1]. **2. Analysis of Incorrect Options:** * **Option A:** This is incorrect. Approximately **10%** of pheochromocytomas are malignant (the "Rule of 10"). Recent data suggests this may be slightly higher (15-17%), but it is nowhere near 50%. * **Option B:** While the **PASS (Pheochromocytoma of the Adrenal Gland Scaled Score)** uses atypia and invasion to *predict* aggressive behavior, these features do not *define* malignancy. Only metastasis does. * **Option C:** This is incorrect. **123I-MIBG scans** are highly sensitive and specific for identifying both the primary tumor and distant metastatic deposits. **Clinical Pearls for NEET-PG:** * **The Rule of 10:** 10% are malignant, 10% are bilateral, 10% are extra-adrenal (Paragangliomas), and 10% occur in children. * **Genetic Association:** Up to 25-30% are now known to be familial (MEN 2A/2B, VHL, NF-1, and SDHB mutations). * **Zellballen Pattern:** The classic histological arrangement of tumor cells in nests surrounded by sustentacular cells. * **Biomarker:** Urinary vanillylmandelic acid (VMA) and plasma metanephrines are used for diagnosis. **References:** [1] Cross SS. Underwood's Pathology: A Clinical Approach. 6th ed. Common Clinical Problems From Liver And Biliary System Disease, pp. 419-420.
Practice by Chapter
Pituitary Gland Disorders
Practice Questions
Thyroid Gland Diseases
Practice Questions
Parathyroid Gland Pathology
Practice Questions
Adrenal Cortical Disorders
Practice Questions
Adrenal Medullary Disorders
Practice Questions
Pancreatic Endocrine Disorders
Practice Questions
Multiple Endocrine Neoplasia Syndromes
Practice Questions
Diffuse Neuroendocrine System
Practice Questions
Pineal Gland Pathology
Practice Questions
Laboratory Diagnosis of Endocrine Diseases
Practice Questions
Want unlimited practice?
Get full access to all questions, explanations, and performance tracking.
Start For Free